$664 Thousand is the total value of COMMODORE CAPITAL LP's 35 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| COGT | COGENT BIOSCIENCES INC | $49,939 | -99.9% | 4,319,940 | 0.0% | 7.53% | -27.4% | |
| CBAY | CYMABAY THERAPEUTICS INC | $35,980 | -99.8% | 5,738,500 | 0.0% | 5.42% | +67.9% | |
| DAWN | DAY ONE BIOPHARMACEUTICALS I | $15,918 | -99.9% | 739,661 | 0.0% | 2.40% | +0.7% | |
| ALLK | ALLAKOS INC | $13,838 | -99.9% | 1,643,500 | 0.0% | 2.08% | +28.9% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $9,739 | -99.9% | 1,325,000 | 0.0% | 1.47% | -4.3% | |
| KPTI | KARYOPHARM THERAPEUTICS INC | $6,581 | -99.9% | 1,935,609 | 0.0% | 0.99% | -41.6% | |
| LRMR | LARIMAR THERAPEUTICS INC | $3,098 | -99.9% | 750,000 | 0.0% | 0.47% | +21.0% | |
| RZLT | REZOLUTE INC | $2,505 | -99.9% | 1,210,000 | 0.0% | 0.38% | -29.1% | |
| KALV | KALVISTA PHARMACEUTICALS INC | $2,113 | -100.0% | 312,553 | 0.0% | 0.32% | -56.4% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.